Oncolytic vaccinia virus combination cancer therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8747837
SERIAL NO

13395929

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SILLAJEN BIOTHERAPEUTICS INC450 SANSOME STREET SUITE 650 SAN FRANCISCO CA 94111

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Breitbach, Caroline San Francisco, US 4 29
Kirn, David San Francisco, US 25 226

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 10, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00